Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers

In the age of personalized medicine stratifying tumors into molecularly defined subtypes associated with distinctive clinical behaviors and predictable responses to therapies holds tremendous value. Towards this end, we developed a custom microfluidics-based bladder cancer gene expression panel for characterization of archival clinical samples. In silico analysis indicated that the content of our panel was capable of accurately segregating bladder cancers from several public datasets into the clinically relevant basal and luminal subtypes. On a technical level, our bladder cancer panel yielded robust and reproducible results when analyzing formalin-fixed, paraffin-embedded (FFPE) tissues. We applied our panel in the analysis of a novel set of 204 FFPE samples that included non-muscle invasive bladder cancers (NMIBCs), muscle invasive disease (MIBCs), and bladder cancer metastases (METs). We found NMIBCs to be mostly luminal-like, MIBCs to include both luminal- and basal-like types, and METs to be predominantly of a basal-like transcriptional profile. Mutational analysis confirmed the expected enrichment of FGFR3 mutations in luminal samples, and, consistently, FGFR3 IHC showed high protein expression levels of the receptor in these tumors. Our bladder cancer panel enables basal/luminal characterization of FFPE tissues and with further development could be used for stratification of bladder cancer samples in the clinic.

[1]  H. Hinterberger.  Exploratory data analysis , 2018, Encyclopedia of Database Systems.

[2]  M. L. Calle,et al.  Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. , 2016, Cancer cell.

[3]  R. Millikan,et al.  A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. , 2016, European urology.

[4]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[5]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[6]  C. Ulrich,et al.  Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. , 2014, Gastroenterology.

[7]  Xavier Paoletti,et al.  EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype , 2014, Science Translational Medicine.

[8]  Rajesh Patel,et al.  Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel , 2014, PloS one.

[9]  X. Liu,et al.  Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. , 2014, Genetics and molecular research : GMR.

[10]  Katherine A. Hoadley,et al.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.

[11]  G. Hampton,et al.  Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers , 2014, PloS one.

[12]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[13]  Kai Wang,et al.  A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma , 2013, Clinical Cancer Research.

[14]  B. Czerniak,et al.  Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer , 2013, Molecular Cancer Therapeutics.

[15]  P. Clark,et al.  Management of superficial and muscle-invasive urothelial cancers of the bladder , 2013, Current opinion in oncology.

[16]  V. Nargund,et al.  Management of non-muscle-invasive (superficial) bladder cancer. , 2012, Seminars in oncology.

[17]  S. Serrano,et al.  Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. , 2012, Human pathology.

[18]  C. Taylor,et al.  Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis , 2012, Clinical Cancer Research.

[19]  Johan Staaf,et al.  Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma , 2012, PloS one.

[20]  M. Ringnér,et al.  A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.

[21]  C. Dinney,et al.  p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers , 2012, PloS one.

[22]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[23]  V. Reuter,et al.  Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma , 2011, The Journal of pathology.

[24]  T. H. van der Kwast,et al.  FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy , 2010, PloS one.

[25]  B. Czerniak,et al.  Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. , 2010, Urologic oncology.

[26]  C. Cordon-Cardo,et al.  Molecular pathways of urothelial development and bladder tumorigenesis. , 2010, Urologic oncology.

[27]  M. Belvin,et al.  Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.

[28]  Eun-Jung Kim,et al.  Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer , 2010, Molecular Cancer.

[29]  Peter A. Jones,et al.  p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Knowles,et al.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer , 2007, The Journal of pathology.

[31]  C. Cordon-Cardo,et al.  Molecular alterations associated with bladder cancer progression. , 2007, Seminars in oncology.

[32]  Ekaterini Blaveri,et al.  Bladder cancer outcome and subtype classification by gene expression. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Casal,et al.  Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation , 2005, Clinical Cancer Research.

[34]  Xue-Ru Wu.  Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[35]  R. Montironi,et al.  Frequent FGFR3 mutations in urothelial papilloma , 2002, The Journal of pathology.

[36]  S. Dudoit,et al.  A prediction-based resampling method for estimating the number of clusters in a dataset , 2002, Genome Biology.

[37]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[38]  T. Carmody,et al.  Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. , 1998, Urology.

[39]  N. Heney,et al.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course. , 1992, The Urologic clinics of North America.

[40]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[41]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[42]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[43]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[44]  M. Knowles.  Tumor suppressor loci in bladder cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[45]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[46]  J. Palou,et al.  Multivariate analysis of the prognostic factors of primary superficial bladder cancer. , 2000, The Journal of urology.

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.